VASSILIS PROTOGEROU

Prof. VASSILIS PROTOGEROU


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2019 in Bioengineering
Verified
Journal Article
Open access
PDF file
VPVASSILIS PROTOGEROU
VASSILIS PROTOGEROU
Efstathios MichalopoulosEfstathios Michalopoulos
Efstathios Michalopoulos
PANAGIOTIS MALLISPANAGIOTIS MALLIS
PANAGIOTIS MALLIS
IGIoanna Gontika
Ioanna Gontika
ZDZetta Dimou
Zetta Dimou
CDCharalampos Deliveliotis
Charalampos Deliveliotis
Erectile dysfunction (ED) affects more than 30 million men; endothelial dysfunction plays a significant role in EDs pathogenesis. The aim of this study was to administer mesenchymal stem cells (MSC) derived from adipose tissue and platelet lysate (PL) into patients with erectile dysfunction. This pilot study enrolled eight patients with diagnosed ED. Patients enrolled were suffering from organic ED due to diabetes melitus, hypertension, hypercholesterolaemia, and Peyronie disease. The patients were distributed in 2 groups. Patients in group A received adipose derived mesenchymal stem cells (ADMSC) resuspended in PL while patients in group B received only PL. ADMSCs were isolated from patients’ adipose tissue and expanded. In addition, blood sampling was obtained from the patients in order to isolate platelet lysate. After the application of the above treatments, patients were evaluated with an International Index of Erectile Function (IIEF-5) questionnaire, penile triplex, and reported morning erections. After MSCs and PL administration, patients presented improved erectile function after 1 and 3 months of follow-up. A statistically significant difference was observed in the IIEF-5 score before and after administration of both treatments after the first month (p < 0.05) and the third month (p < 0.05). No statistically significant difference was observed in the IIEF-5 score between group A and B patients. All patients were characterized by improved penile triplex and increased morning erections. No severe adverse reactions were observed in any patient except a minor pain at the site of injection, which was in the limits of tolerability. The results of this study indicated the satisfactory use of MSCs and PL in ED. MSCs in combination with PL or PL alone seems to be very promising, especially without having the negative effects of the current therapeutic treatment.

6 January 2021 in Medicines
Verified
Journal Article
Open access
PDF file
VPVASSILIS PROTOGEROU
VASSILIS PROTOGEROU
DCDimosthenis Chrysikos
Dimosthenis Chrysikos
VKVasileios Karampelias
Vasileios Karampelias
YSYpatios Spanidis
Ypatios Spanidis
SBSara El Bisari
Sara El Bisari
TTTheodore Troupis
Theodore Troupis
Erectile dysfunction (ED) is a disorder that affects the quality of life and the sexual relations of more than half of the male population aged over 40 years. The prediction regarding the incidence of ED is devastating as it is expected that this disorder will affect more than 300 million men in the next five years. Several studies have suggested the use of stem cells for the treatment of ED and showed that this type of treatment is promising in terms of damaged tissue repair as well as of clinical efficacy; however, there are several gaps in the knowledge and evidence is lacking. In order to highlight a few of them in this review, we performed a research of the literature focusing on currently available clinical studies regarding the clinical efficacy of stem cell administration for the treatment of ED. We reviewed the methods of administration, the cell types used in the performed clinical trials and the safety and efficiency of such procedures. We conclude that there are rapidly expanding and promising results from the reported clinical studies indicating that stem cells could indeed be a potential treatment for patients with ED although more studies are necessary.

18 March 2020 in Medicines
Verified
Journal Article
Open access
PDF file
VPVASSILIS PROTOGEROU
VASSILIS PROTOGEROU
SBSara El Beshari
Sara El Beshari
Efstathios MichalopoulosEfstathios Michalopoulos
Efstathios Michalopoulos
PANAGIOTIS MALLISPANAGIOTIS MALLIS
PANAGIOTIS MALLIS
DCDimosthenis Chrysikos
Dimosthenis Chrysikos
TTTheodore Troupis
Theodore Troupis
Background: The current treatment of Erectile Dysfunction (ED) is mainly based on the use of drugs that provide erections shortly after use but they do not really treat the problem. Stem cell therapy is a novel treatment with regenerative properties that can possibly treat erectile dysfunction. Methods: Five patients with erectile disease were treated with Adipose-Derived Stem Cells (ADSCs) and Platelet Lysate Plasma (PLP). ADSCs were obtained through abdominal liposuction and PLP was prepared after obtaining blood samples from peripheral veins. Erectile function was evaluated with the International Index of Erectile Function questionnaire (IIEF-5) questionnaire, penile triplex at the 1st, 3rd, 6th and 12th month post-treatment. A CT scan of the head, thorax and abdomen was done before treatment and at the 12th month. Results: IIEF-5 scores were improved in all patients at the 6th month although not in the same pattern in all patients. Peak Systolic Velocity (PSV) also improved at the 6th month in all patients but also with different patterns in each patient, while End Diastolic Velocity (EDV) was more variable. Two patients decreased the treatment they used in order to obtain erection (from Intracavernosal injections (ICI) they used PDE-5Is), two had unassisted erections and one had an initial improvement which decreased at the 6th month. There were no side effects noted. Conclusions: Stem cell therapy in combination with PLP appears to show some improvement in erectile function and has minimal side effects in the short term.

1 January 2010 in Urology
Verified
Journal Article
Closed access
VPVASSILIS PROTOGEROU
VASSILIS PROTOGEROU
VAVassilis Argyropoulos
Vassilis Argyropoulos
KPKostas Patrozos
Kostas Patrozos
PTPanagiotis Tekerlekis
Panagiotis Tekerlekis
AKAthanassios Kostakopoulos
Athanassios Kostakopoulos

11 May 2022 in Cureus
Verified
Journal Article
Open access
KMKonstantinos Manolakos
Konstantinos Manolakos
KZKonstantinos Zygogiannis
Konstantinos Zygogiannis
CMChagigia Mousa
Chagigia Mousa
TDTheano Demesticha
Theano Demesticha
VPVASSILIS PROTOGEROU
VASSILIS PROTOGEROU
TTTheodore Troupis
Theodore Troupis
Several anatomical variations of the iliohypogastric nerve branches have been observed in earlier studies. Knowledge of these variations is useful for the improvement of peripheral nerve blocks and avoidance of iatrogenic nerve injuries during surgeries. The purpose of this study was to perform a systematic review of the literature about the anatomical topography and variations of the iliohypogastric nerve. An extensive search on PubMed, Scopus, and Web of Science electronic databases was conducted by the first author in November 2021, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Anatomical or cadaveric studies about the origin, the course, and the distribution of the iliohypogastric nerve were included in this review. Thirty cadaveric studies were included for qualitative analysis. Several anatomical variations of the iliohypogastric nerve were depicted including its general properties, its origin, its branching patterns, its course, its relation to anatomical landmarks, and its termination. Among them, the absence of the iliohypogastric nerve ranged from 0 to 34%, its origin from L1 ranged from 62.5 to 96.5%, and its isolated emergence from psoas major ranged from 47 to 94.5%. Numerous anatomical variations of the iliohypogastric nerve exist but are not commonly cited in classic anatomical textbooks. The branches of the iliohypogastric nerve may be damaged during spinal anesthesia and surgical procedures in the lower abdominal region. Therefore, a better understanding of the regional anatomy and its variations is of vital importance for the prevention of iliohypogastric nerve injuries.

26 November 2010
Verified
Journal Article
Closed access
VPVASSILIS PROTOGEROU
VASSILIS PROTOGEROU
SASofia Anagnostopolou
Sofia Anagnostopolou
DVDionissis Venierates
Dionissis Venierates
TTTheodore Troupis
Theodore Troupis
MPMara Plagou
Mara Plagou
PSPanagiotis Skandalakis
Panagiotis Skandalakis